文献速递重症综合管理与镇静镇痛

重症患者维生素C药代动力学:四种静脉给药方案的随机试验

Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens.
PubMed 文献 · Chest · 2018-03-06
一句话结论重症多器官功能障碍患者中,2 g/d 维生素C使血浆浓度达正常范围,10 g/d 达超正常范围并伴草酸排泄增加和代谢性碱中毒。

该研究为四组随机药代动力学试验,纳入20例重症多器官功能障碍患者,随机接受维生素C 2 g/d或10 g/d,分每日两次推注或持续输注48小时。用NONMEM建立二室药代动力学模型,以肌酐清除率和体重为协变量描述四种方案。2 g/d推注1小时浓度为29-50 mg/L、谷浓度5.6-16 mg/L;2 g/d持续输注48小时稳态浓度7-37 mg/L;10 g/d推注1小时浓度186-244 mg/L、谷浓度14-55 mg/L;10 g/d持续输注48小时稳态浓度40-295 mg/L。10 g/d剂量组草酸排泄和碱剩余增加,停药48小时后15%患者血浆浓度降至维生素缺乏水平。

要点

  • 2 g/d 维生素C(推注或持续)使重症患者血浆浓度达正常范围,10 g/d 达超正常范围
  • 10 g/d 组草酸排泄和碱剩余增加,提示代谢性碱中毒风险
  • 停药48小时后15%患者血浆浓度降至维生素缺乏水平,需持续治疗预防
  • 二室药代动力学模型以肌酐清除率和体重为独立协变量,最佳描述四种方案
  • 2 g/d 推注1小时浓度29-50 mg/L、谷浓度5.6-16 mg/L;2 g/d 持续48小时稳态7-37 mg/L

适用人群与场景

  • 重症多器官功能障碍患者

处置流程与药物剂量

  • 维生素C 2 g/d 或 10 g/d,分每日两次推注或持续输注,疗程48小时

研究设计与关键结果

  • 四组随机药代动力学试验,纳入20例重症多器官功能障碍患者,随机接受2 g/d或10 g/d维生素C,分每日两次推注或持续输注48小时
  • 2 g/d推注:1小时血浆浓度29-50 mg/L,谷浓度5.6-16 mg/L;2 g/d持续:48小时稳态浓度7-37 mg/L
  • 10 g/d推注:1小时浓度186-244 mg/L,谷浓度14-55 mg/L;10 g/d持续:48小时稳态浓度40-295 mg/L
  • 10 g/d剂量组草酸排泄和碱剩余增加
  • 停药48小时后15%患者血浆浓度降至维生素缺乏水平

证据类型、等级与局限

  • 证据类型:四组随机药代动力学试验
  • 局限:原文未报告局限性

对床旁实践的改变

  • 2 g/d维生素C与正常血浆浓度相关,10 g/d与超正常血浆浓度、草酸排泄增加和代谢性碱中毒相关
  • 需持续治疗以预防维生素缺乏

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Early high-dose IV vitamin C is being investigated as adjuvant therapy in patients who are critically ill, but the optimal dose and infusion method are unclear. The primary aim of this study was to describe the dose-plasma concentration relationship and safety of four different dosing regimens.

METHODS: This was a four-group randomized pharmacokinetic trial. Patients who were critically ill with multiple organ dysfunction were randomized to receive 2 or 10 g/d vitamin C as a twice daily bolus infusion or continuous infusion for 48 h. End points were plasma vitamin C concentrations during 96 h, 12-h urine excretion of vitamin C, and oxalate excretion and base excess. A population pharmacokinetic model was developed using NONMEM.

RESULTS: Twenty patients were included. A two-compartment pharmacokinetic model with creatinine clearance and weight as independent covariates described all four regimens best. With 2 g/d bolus, plasma vitamin C concentrations at 1 h were 29 to 50 mg/L and trough concentrations were 5.6 to 16 mg/L. With 2 g/d continuous, steady-state concentrations were 7 to 37 mg/L at 48 h. With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L. With 10 g/d continuous, steady-state concentrations were 40 to 295 mg/L at 48 h. Oxalate excretion and base excess were increased in the 10 g/d dose. Forty-eight hours after discontinuation, plasma concentrations declined to hypovitaminosis levels in 15% of patients.

CONCLUSIONS: The 2 g/d dose was associated with normal plasma concentrations, and the 10 g/d dose was associated with supranormal plasma concentrations, increased oxalate excretion, and metabolic alkalosis. Sustained therapy is needed to prevent hypovitaminosis.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02455180; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. de Grooth HJ, Manubulu-Choo WP, Zandvliet AS, et al. Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. Chest. 2018. PMID: 29522710. doi:10.1016/j.chest.2018.02.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。